| Bioactivity | PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides 1010pT, cdc25c and PBIP, with IC50s of 1.6, 0.8 and 1.4 μM, respectively. PLK1-IN-9 inhibits proliferations of cancer cells HeLa, HL60, SNU387/499, HepG2, exhibits cytotoxicity and induces apoptosis. PLK1-IN-9 inhibits tumor growth in HepG2 xenograft mouse model[1]. |
| CAS | 893772-67-3 |
| Formula | C12H7F3N4O2 |
| Molar Mass | 296.20 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kin K, et al., Pharmaceutical composition for preventing or treating cancer, containing activation inhibitor of plk1 as active ingredient. WO2020111325. |
PLK1-IN-9
CAS: 893772-67-3 F: C12H7F3N4O2 W: 296.20
PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.